Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic

Phase 2

Completed

• Conditions: Circulating Tumor Cells; Chemotherapy; Prostate Carcinoma; Castration-resistant Prostate Cancer
• Interventions: Drug: Cabazitaxel; Drug: Docetaxel

• Registration Number: NCT03101046
• Lead Sponsor: UNICANCER

Brief Summary

This study compares the biological activity of cabazitaxel (6 cycles) to that of docetaxel (6 cycles) in metastatic castrate-resistant prostate cancer (mCRPC) patients with docetaxel resistant mCRPC defined as ≥5 circulating tumor cells (CTCs) / 7.5 mL after 2 cycles of docetaxel.

Patients with docetaxel resistant metastatic castration-resistant prostate cancer (mCRPC) based on circulating tumor cell (CTC) enumeration (patients with ≥5 CTCs / 7.5 mL before docetaxel chemotherapy and after 2 cycles of docetaxel) will receive either 6 additional cycles of docetaxel or 6 additional cycles of cabazitaxel after randomisation.

A cohort of patients with docetaxel sensitive metastatic castration-resistant prostate cancer (mCRPC) based on circulating tumor cell (CTC) enumeration (patients ≥5 CTCs / 7.5 mL before docetaxel chemotherapy and \<5 CTCs / 7.5 mL after 2 cycles of docetaxel) will receive 6 additional cycles of docetaxel.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-03-22
• Study First Submitted QC: 2017-04-03
• Study First Posted: 2017-04-04
• Study Start: 2018-11-15
• Primary Completion: 2021-12-31
• Study Completion: 2021-12-31
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-09
• Last Update Posted: 2022-02-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

1. Written informed consent signed prior any study-related procedures
2. Adult men ≥18 years
3. Histologically confirmed prostate adenocarcinoma
4. Metastatic disease as evidenced by imaging (bone scan, CT-scan, MRI and/or PET-choline).
5. Documented progressive disease while receiving continuous hormonal treatment with luteinizing hormone-releasing hormone (LH-RH) agonist or antagonist or after surgical castration (at least one visceral or soft tissue metastatic lesion, including a new lesion). Patient with non-measurable disease must have documented rising prostate-specific antigen (PSA) levels or appearance of new lesion
6. Effective castration assessed by testosterone levels ≤50 ng/dL
7. Patients with a Eastern Cooperative Oncology Group (ECOG) performance status ≤2
8. Patients affiliated to social security scheme

Exclusion Criteria

1. Prior chemotherapy for metastatic prostate cancer except estramustine <1 year from the end of adjuvant and/or neoadjuvant chemotherapy for localized disease <1 year from the end of chemotherapy for de novo metastatic prostate cancer
2. Prior isotope therapy, whole pelvic radiotherapy or radiotherapy to >30% of bone marrow
3. Less than 1 month elapsed from prior treatment with radiotherapy, surgery and less than 2 weeks from any previous hormonal treatment except for LH-RH agonists/antagonists (which are to be continued). Patients may be treated with bisphosphonates prior to study entry which should be pursued,
4. History of brain metastases, uncontrolled spinal cord compression, carcinomatous meningitis or new evidence of brain or leptomeningeal disease
5. Patient with any of the following abnormal laboratory tests: hemoglobin <10 g/dL, absolute neutrophil count <1.5 x 10⁹/L, platelets <100 x 10⁹/L, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >1.5 x upper limit of normal (ULN), total bilirubin >1.0 ULN, creatinine clearance <40 ml/mn (MDRD)
6. History of hypersensitivity to polysorbate 80 or docetaxel
7. Contraindication to the use of corticosteroids
8. Peripheral neuropathy grade ≥2 according to NCI CTCAE v4.0
9. Ventricular ejection fraction <50% (echography or scintigraphy)
10. Any of the following within 6 months prior to study entry: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) class III or IV congestive heart failure, stroke or transient ischemic attack
11. Any of the following within 3 months prior to study entry: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, inflammatory bowel disease, pulmonary embolism or other uncontrolled thromboembolic event
12. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormally that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
13. Planned vaccination with a live or live-attenuated vaccines
14. Participation in another clinical trial and any treatment with any investigational drug within 30 days prior to randomization
15. Any illness or problem including geographic, psychiatric or psychological which is incompatible with being monitored during the trial
16. Patients with reproductive potential who do not agree to use effective method of contraception during the treatment
17. Person deprived of their liberty or under protective custody or guardianship

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group1: Arm A (standard arm) + Arm B (experimental arm)	Cabazitaxel	Arm A: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks) after randomization. Arm B: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 10 cycles of cabazitaxel (20 mg/m² every 3 weeks) after randomization.
Group1: Arm A (standard arm) + Arm B (experimental arm)	Docetaxel	Arm A: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks) after randomization. Arm B: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 10 cycles of cabazitaxel (20 mg/m² every 3 weeks) after randomization.
Group 2: Cohort	Docetaxel	Patients with docetaxel sensitive mCRPC (defined as having \<5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks)

Primary Outcome Measures

Name	Time	Method
Biological activity of chemotherapy	18 weeks after randomisation	Biological activity of chemotherapy as defined as \< 5 CTCs per 7.5 ml at the end of chemotherapy with docetaxel or cabazitaxel.

Trial Locations

Locations (5)

ICO-Site René Gauducheau; 🇫🇷 Saint-Herblain, France

Centre Léon Berard; 🇫🇷 Lyon, France

CHD Vendée; 🇫🇷 La Roche-sur-Yon, France

ICO-Site Paul Papin; 🇫🇷 Angers, France

Stéphane CULINE; 🇫🇷 Paris, France